MX337922B - Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable. - Google Patents

Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.

Info

Publication number
MX337922B
MX337922B MX2011006376A MX2011006376A MX337922B MX 337922 B MX337922 B MX 337922B MX 2011006376 A MX2011006376 A MX 2011006376A MX 2011006376 A MX2011006376 A MX 2011006376A MX 337922 B MX337922 B MX 337922B
Authority
MX
Mexico
Prior art keywords
treatment
combination
photodynamic therapy
vegf agents
choroidal neovasculature
Prior art date
Application number
MX2011006376A
Other languages
English (en)
Other versions
MX2011006376A (es
Inventor
H Andrew Strong
Yong Hao
Original Assignee
Valeant Pharmaceuticals Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals Int filed Critical Valeant Pharmaceuticals Int
Publication of MX2011006376A publication Critical patent/MX2011006376A/es
Publication of MX337922B publication Critical patent/MX337922B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describe el uso de una combinación de terapia fotodinámica y un agente anti-VEGF en el tratamiento de condiciones caracterizadas por neovasculatura coroidal indeseable. Estas condiciones incluyen la degeneración macular relacionada con la edad. Los agentes anti-VEGF preferidos son anticuerpos tales como bevacizumab o ranibizumab. Los fotosensibilizadores se pueden seleccionar de porfirinas verdes tal como BPD-MA (verteporfina) y la activación fotodinámica del fotosensibilizador se puede realizar usando una tasa de fluencia reducida. El uso además puede comprender un agente antiinflamatorio tal como dexametasona.
MX2011006376A 2008-12-16 2009-12-16 Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable. MX337922B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13805908P 2008-12-16 2008-12-16
US18294309P 2009-06-01 2009-06-01
PCT/CA2009/001857 WO2010069073A1 (en) 2008-12-16 2009-12-16 Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature

Publications (2)

Publication Number Publication Date
MX2011006376A MX2011006376A (es) 2012-12-17
MX337922B true MX337922B (es) 2016-03-28

Family

ID=42268233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006376A MX337922B (es) 2008-12-16 2009-12-16 Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.

Country Status (10)

Country Link
US (1) US9226917B2 (es)
EP (1) EP2379109B1 (es)
JP (1) JP5988584B2 (es)
KR (1) KR101692459B1 (es)
CN (1) CN102325550B (es)
AU (1) AU2009327266B2 (es)
CA (1) CA2747219C (es)
MX (1) MX337922B (es)
SG (1) SG172126A1 (es)
WO (1) WO2010069073A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX337922B (es) 2008-12-16 2016-03-28 Valeant Pharmaceuticals Int Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.
EP3019526A1 (en) * 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
US9683102B2 (en) 2014-05-05 2017-06-20 Frontier Scientific, Inc. Photo-stable and thermally-stable dye compounds for selective blue light filtered optic
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230167170A1 (en) * 2020-05-01 2023-06-01 Cellviva, LLC Compositions comprising anti-vegf and nanoparticles and methods of using the same for the treatment of abnormal or excessive angiogenesis
US11684799B2 (en) 2021-08-28 2023-06-27 Cutera, Inc. Image guided laser therapy
US20240366565A1 (en) * 2021-09-09 2024-11-07 The Board Of Trustees Of The Leland Stanford Junior University Use of Verteporfin to Modulate Wound Healing After an Ocular Surgical Procedure or Ocular Injury
CN114949208B (zh) * 2022-05-06 2023-07-04 温州医科大学 纳米光动力材料及其脉络膜新生血管的治疗的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5308608A (en) 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
US5726304A (en) 1992-10-30 1998-03-10 The University Of British Columbia Porphocyanine and CNC-expanded porphyrins
US5405957A (en) 1992-10-30 1995-04-11 The University Of British Columbia Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US5703230A (en) 1994-12-02 1997-12-30 University Of British Columbia Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same
CA2221912A1 (en) 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
CA2437557C (en) 2001-02-06 2012-07-24 Qlt Inc. Reduced total fluence photodynamic therapy of choroidal neovasculature in amd
WO2002062385A2 (en) * 2001-02-06 2002-08-15 Qlt, Inc. Method to prevent vision loss
WO2002064163A2 (en) * 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
JP2005511576A (ja) 2001-11-09 2005-04-28 アイテック・ファーマシューティカルズ 眼球血管新生病を治療する方法
ATE442861T1 (de) * 2003-03-07 2009-10-15 Univ Texas Gegen antikörper gerichtete photodynamische therapie
CA2523605A1 (en) * 2003-03-10 2004-09-23 Charles W. Spangler Targeted agents for both photodiagnosis and photodynamic therapy
WO2007038453A2 (en) * 2005-09-26 2007-04-05 Advanced Ocular Systems Limited Use of an anti-vascular endothelial growth factor (vegf) agent to ameliorate inflammation
US20070072933A1 (en) * 2005-09-26 2007-03-29 Peyman Gholam A Delivery of an ocular agent
MX337922B (es) 2008-12-16 2016-03-28 Valeant Pharmaceuticals Int Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.
US20120244147A1 (en) * 2009-08-17 2012-09-27 Theuer Charles P Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
US8852498B1 (en) 2011-04-20 2014-10-07 Imaging Systems Technology, Inc. Beryllium microspheres

Also Published As

Publication number Publication date
US9226917B2 (en) 2016-01-05
KR20110122668A (ko) 2011-11-10
WO2010069073A1 (en) 2010-06-24
CA2747219C (en) 2017-12-12
JP2012512184A (ja) 2012-05-31
US20120041356A1 (en) 2012-02-16
EP2379109A4 (en) 2012-06-20
EP2379109B1 (en) 2020-10-07
CN102325550B (zh) 2016-10-26
AU2009327266B2 (en) 2015-10-29
KR101692459B1 (ko) 2017-01-03
AU2009327266A1 (en) 2011-07-14
JP5988584B2 (ja) 2016-09-07
SG172126A1 (en) 2011-07-28
EP2379109A1 (en) 2011-10-26
CA2747219A1 (en) 2010-06-24
MX2011006376A (es) 2012-12-17
CN102325550A (zh) 2012-01-18

Similar Documents

Publication Publication Date Title
MX337922B (es) Combinacion de terapia fotodinamica y agentes anti-vegf en el tratamiento de neovasculatura coroidal indeseable.
Dichiara et al. Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents
Lan et al. Nanoscale metal–organic frameworks for phototherapy of cancer
Lin et al. Near-infrared light activated delivery platform for cancer therapy
IT1333697B (es)
WO2009097468A3 (en) Drug delivery devices, kits and methods therefor
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CR8711A (es) Indazoles, benzotiazoles, benzoisotiazoles, benzisoxazoles y preparacion y usos de estos
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
AR037307A1 (es) Metodos para el tratamiento de enfermedades oculares neovasculares
GB2442915B (en) Perylenequinone derivatives and uses thereof
MX360683B (es) Sensibilizantes de (bacterio) clorofila para el tratamiento de enfermedades y transtornos oculares campo tecnico.
PH12019500861A1 (en) Novel chlorin e6 derivative and pharmaceutically-acceptable salts thereof, preparation method therefor, and application thereof
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
WO2007138490A3 (en) Photodynamic therapy for treatng age-related macular degeneration
UY28271A1 (es) Compuestos químicos
WO2022245933A8 (en) Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment
PE20150965A1 (es) Azaindolinas
WO2007087462A3 (en) Methods and compositions for cancer therapy using a novel adenovirus
WO2006091666A3 (en) Methods and compositions for treating conditions of the eye
KR20180084335A (ko) 적색형광단백질을 발현하는 유전자 및 틴 에틸 에티오푸르푸린을 이용한 광역학 치료용 조성물 및 이를 이용한 광역학 치료방법
MX2022000841A (es) Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias.
NZ760040A (en) Methods of treating brain tumors using combination therapy
AR070975A1 (es) Tratamiento para trastornos relacionados con los ojos, composicion y uso
BR112021017587A2 (pt) Formulações tópicas contendo fotossensibilizadores de ftalocianina

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

FG Grant or registration